• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»BRII-179-002 study

Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?

By Pallavi Madhiraju on April 26, 2026   Pharma & Biotech  

Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?

HBV cure hopes depend on durability, not just antigen loss. Brii Bio’s APASL data shifts attention to post-treatment control.

Recent Posts

  • AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics
  • Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment
  • Lucerno Dynamics asset deal gives Radnostix new route into nuclear medicine workflows
  • Butterfly Network enters Brazil with iQ+ and iQ3 handheld ultrasound systems
  • Endologix DETOUR2 three-year data strengthen case for percutaneous bypass in complex SFA disease
  • Why Permeasis MTD4 could reshape enzyme replacement and intracellular drug discovery
  • Oliva Therapeutics targets thyroid treatment demand with U.S.-made Amerithroid tablets
  • ITI-9001 enters Phase 1 as Immunomic Therapeutics tests disease-modifying allergy vaccine
  • Visby Medical’s FDA-cleared at-home PCR could reshape flu and COVID-19 testing
  • Is Vilo Signal OS truly different from Oura Advisor and WHOOP’s proactive AI?
  • Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
  • Why the Nona Biosciences and Lonza alliance matters for brain-penetrant biologics
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes